Piyasa açık· · USD · Veriler gecikmeli olabilir
Fiyatlar gecikmeli olabilir ve yalnızca bilgilendirme amaçlıdır - yatırım tavsiyesi değildir.
Temettüler dahil toplam getiri.
NEW YORK and WALTHAM, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced one oral presentation and four poster presentations for claseprubart at the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place September 29 to October 2, 2026 in Orlando, Flo
Dianthus Therapeutics (DNTH) has moved into the capital markets spotlight after filing a US$500 million follow on equity offering of common stock alongside a broad universal shelf registration. The capital raise comes after a sharp pullback in Dianthus Therapeutics' share price. The stock fell 4.99% over the last session, 8.83% across the past week and 15.11% over 30 days. However, the 90-day share price return of 2.04% and a year-to-date share price gain of 135.48% suggest that momentum has...
Fiyatın 50 ve 200 günlük hareketli ortalamalara göre konumu.
Makkler Adil Değer, finansal sağlık skoru, analist görüşü, benzer şirketler ve MakklerAI.
Dianthus Therapeutics has delivered a very large 3 year return, which puts a lot of focus on whether the current share price still lines up with what its balance sheet actually supports. With the stock last closing at US$93.44, the open question is how that level stacks up against the book value backing each share. Over the past 3 years the stock has gained roughly 7x. Anyone looking at Dianthus Therapeutics now has to ask whether that kind of move is still grounded in the company’s...
Üçüncü taraf yayıncıların bu şirket hakkındaki son başlıkları; Makkler'in kendi editoryal içeriğinden ayrı tutulur ve dış kaynağa yönlendirir. Başlıkların doğruluğu ilgili yayıncının sorumluluğundadır.